Rolke James 4

What Happened

• James Rolke, CEO of Revelation Biosciences (REVB), had 8,521 shares disposed on February 3, 2026 to satisfy tax withholding obligations tied to the vesting of restricted stock awards. The weighted average price reported was $1.86 per share, for total proceeds of approximately $15,849. The disposition was a mandatory tax-withholding sale, not an open-market discretionary sale.

Key Details

• Transaction date: 2026-02-03; Form 4 filed: 2026-02-05.
• Shares disposed: 8,521; weighted average price: $1.86; total value: ~$15,849.
• Price range reported: $1.85–$1.87 across multiple transactions (footnote).
• Footnotes:
  • F1: Share counts reflect a 1-for-4 reverse split effective Jan 28, 2026.
  • F2: Shares were sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding upon RSU vesting; the sale was mandatory and not at the reporting person's discretion.
  • F3: Price shown is a weighted average; individual sale prices ranged $1.85–$1.87.
• Shares owned after the transaction: not specified in the provided filing.
• Filing timeliness: Form 4 filed two days after the transaction date; no indication in the provided data that the filing was late.

Context

• Transaction code F denotes a tax-withholding sale tied to restricted stock vesting. Such mandatory sales are routine administrative actions and do not necessarily indicate the insider's view on the company's stock. The reverse split footnote means reported share counts are post-split figures.